OTC Markets OTCQX - Delayed Quote USD
Bayer Aktiengesellschaft (BAYRY)
10.94 +0.13 (+1.20%)
At close: June 23 at 4:00:00 PM EDT
Chart Range Bar
Loading chart for BAYRY
- Previous Close
10.81 - Open
11.27 - Bid 11.24 x 245800
- Ask 11.25 x 220000
- Day's Range
11.18 - 11.39 - 52 Week Range
7.19 - 14.85 - Volume
69,052 - Avg. Volume
1,451,790 - Market Cap (intraday)
42.991B - Beta (5Y Monthly) 0.85
- PE Ratio (TTM)
-- - EPS (TTM)
-0.65 - Earnings Date (est.) Aug 4, 2026
- Forward Dividend & Yield 0.03 (0.29%)
- Ex-Dividend Date Apr 28, 2026
- 1y Target Est
14.19
Recent News
View More
Performance Overview
Trailing total returns as of 6/24/2026, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .
YTD Return
BAYRY
1.51%
DAX P (^GDAXI)
1.02%
1-Year Return
BAYRY
43.81%
DAX P (^GDAXI)
4.65%
3-Year Return
BAYRY
19.43%
DAX P (^GDAXI)
56.29%
5-Year Return
BAYRY
21.58%
DAX P (^GDAXI)
58.70%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 6/24/2026
Market Cap
43.33B
Enterprise Value
76.01B
Trailing P/E
--
Forward P/E
9.03
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.86
Price/Book (mrq)
1.34
Enterprise Value/Revenue
1.47
Enterprise Value/EBITDA
21.04
Financial Highlights
Profitability and Income Statement
Profit Margin
-4.76%
Return on Assets (ttm)
3.64%
Return on Equity (ttm)
-6.93%
Revenue (ttm)
45.24B
Net Income Avi to Common (ttm)
-2.16B
Diluted EPS (ttm)
-0.65
Balance Sheet and Cash Flow
Total Cash (mrq)
6.66B
Total Debt/Equity (mrq)
134.27%
Levered Free Cash Flow (ttm)
7.31B
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
15.63
-0.82%
Mkt Cap 28.441B
Industry Drug Manufacturers—General
Mkt Cap undefined -
Industry -
Research Reports
View MoreBayer Earnings: On Track to Deliver Full-Year Guidance
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
RatingPrice TargetBayer Earnings: Guidance in Line With Expectations, Currency Rates Likely to Be a Headwind
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
RatingPrice TargetBayer: Glyphosate Settlement Removes Litigation Overhang Despite Higher Provisions
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (39% of total sales in 2024) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (49% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
RatingPrice TargetBayer: Glyphosate Settlement Removes Litigation Overhang Despite Higher Provisions
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (39% of total sales in 2024) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (49% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
RatingPrice Target